Established and emerging neuromodulation for drug-resistant epilepsy

Area of Science:

• Neurology
• Biomedical Engineering
• Neurosurgery

Background:

• Drug-resistant epilepsy affects approximately 30% of patients, limiting treatment options.
• Established invasive neuromodulation (VNS, DBS, RNS) offers significant seizure reduction but carries risks.
• Non-invasive and minimally invasive techniques are emerging as alternatives.

Purpose of the Study:

• To provide a comprehensive comparison of established and novel neuromodulation techniques for drug-resistant epilepsy.
• To analyze mechanisms of action, clinical indications, efficacy, and safety profiles.
• To guide tailored treatment strategies for individual patients.

Main Methods:

• Narrative review of established and emerging neuromodulation techniques.
• Comparison of invasive (VNS, DBS, RNS, FCS) and non-invasive (TNS, TMS, FUS) methods.
• Analysis of seizure reduction efficacy, safety, and limitations.

Main Results:

• Established invasive methods show responder rates around 40% with potential complications.
• Emerging techniques like FCS, TNS, TMS, and FUS offer less invasive or focal alternatives.
• Preliminary data suggests potential efficacy for newer methods, but evidence is less mature.

Conclusions:

• Neuromodulation offers viable options for drug-resistant epilepsy, with both established and emerging techniques.
• The choice of treatment should be individualized based on efficacy, safety, and patient-specific factors.
• Further research is needed to mature evidence for newer, less invasive neuromodulation approaches.